Luigi Bertoli, MD
Hematology · Birmingham, ALNPI 1164514386
Payments from drug & device makers
Across 317 payments — averaging $19.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$718
- Johnson & Johnson$665
- Novartis$663
- Octapharma USA, Inc.$480
- CSL Behring$380
- E.r. Squibb & Sons, L.L.C.$363
- plus $3K from 34 others
What the payments were for
- Food & beverage$5,96794%
- Education$3706%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $718 |
| Johnson & Johnson(2 entities) | 30 | $665 |
| Novartis | 34 | $663 |
| Octapharma USA, Inc. | 19 | $480 |
| CSL Behring | 12 | $380 |
| E.r. Squibb & Sons, L.L.C. | 22 | $363 |
| AbbVie | 16 | $328 |
| Genentech USA, Inc. | 18 | $318 |
| Amgen | 16 | $314 |
| GSK | 17 | $298 |
| Incyte Corporation | 10 | $285 |
| AstraZeneca(2 entities) | 9 | $219 |
| Seagen Inc. | 8 | $134 |
| Pharmaessentia USA Corporation | 4 | $113 |
| Beigene USA, Inc. | 5 | $95 |
| Array Biopharma Inc | 6 | $86 |
| Pharmacyclics LLC, An Abbvie Company | 5 | $79 |
| Karyopharm Therapeutics Inc. | 4 | $66 |
| Insmed, Inc. | 2 | $60 |
| Mylan Institutional Inc. | 3 | $60 |
| Bristol Myers Squibb | 3 | $57 |
| Sanofi | 3 | $56 |
| Boehringer Ingelheim | 3 | $55 |
| Acrotech Biopharma Inc. | 2 | $46 |
| Bayer | 2 | $35 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Global Blood Therapeutics, Inc. | 2 | $32 |
| Shield Therapeutics Inc | 2 | $32 |
| Exelixis Inc. | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Sobi, Inc | 2 | $29 |
| Rigel Pharmaceuticals, Inc. | 2 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $20 |
| Tempus AI, Inc | 1 | $17 |
| Gilead | 1 | $16 |
| Grifols USA, LLC | 1 | $15 |
| Pharmacosmos Therapeutics Inc. | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
How this compares
Too few hematology providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 22 | $439,544 |
| HizentraImmun Glob G(Igg)/Pro/Iga 0-50 | 18 | $290,777 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 28 | $270,689 |
| LynparzaOlaparib | 11 | $212,405 |
| VenclextaVenetoclax | 13 | $191,730 |
| Lenalidomide | 20 | $165,856 |
| PromactaEltrombopag Olamine | 11 | $140,238 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 11 | $90,398 |
| EliquisApixaban | 84 | $56,837 |
| XareltoRivaroxaban | 42 | $50,481 |
| Demeclocycline Hcl | 13 | $5,176 |
| ValacyclovirValacyclovir Hcl | 59 | $2,811 |
| Anagrelide Hcl | 11 | $2,091 |
| Mycophenolate Mofetil | 20 | $1,080 |
| Morphine Sulfate ErMorphine Sulfate | 13 | $1,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $285 | $439,54422 claims |
| PfizerOctagam, Eliquis | $718 | $327,526112 claims |
| CSL BehringHizentra | $380 | $290,77718 claims |
| AstraZenecaLynparza | $219 | $212,40511 claims |
| AbbVieVenclexta | $328 | $191,73013 claims |
| NovartisPromacta | $663 | $140,23811 claims |
| Johnson & JohnsonXarelto | $665 | $50,48142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Alabamaon file to place this against a meaningful peer group, so we don't.
Other hematology in Birmingham
- Katia KhouryBirmingham$362K
- Jason WickerBirmingham$258
- Jacek PolskiMobile$28
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.